 |
|
Technology – PH Pharmaceuticals (PHP) has an issued patent on pharmaceutical aerosol technologies capable of mitigating or reversing the pulmonary clearance defects associated with cystic fibrosis (CF). The technology was discovered by Dr. George Scheele and his coworkers at Harvard Medical School based on 14 papers published between 1990 and 2001. These studies defined the ultimate biochemical deficiency associated with CF. A synopsis of these studies may be found under Scientist. Proof of Concept Human Trials – Under the supervision of Dr. Joseph Pilewski at the University of Pittsburgh Medical Center, IRB-sponsored “Proof-of-Concept” trials in cystic fibrosis patients have demonstrated both the safety and efficacy of the PHP technology. Proof of Concept trials continue in an effort to determine the efficacy of PHP's technology in subgroups of CF patients. Strategic Partnership - A strategic partnership has been formed between PHP and the Battelle Corporation in Columbus , OH , to provide the commercial formulation and to conduct the animal toxicology studies as part of drug development activities to commercialize PHP's technology for the treatment of cystic fibrosis |
|
 |